Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 7/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 5/20 | 0.40 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 2/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.39 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8817388 | 1.00 | CAPN1 (0.46) | CAPN1SLC7A5CTSBLARS1SCN9A | |
| SCHEMBL9572309 | 1.00 | CAPN1 (0.46) | CAPN1SLC7A5CTSBLARS1SCN9A | |
| SCHEMBL3487246 | 1.00 | CAPN1 (0.46) | CAPN1SLC7A5CTSBLARS1SCN9A | |
| SCHEMBL16565969 | 1.00 | CAPN1 (0.46) | CAPN1SLC7A5CTSBLARS1SCN9A | |
| SCHEMBL16897943 | 0.92 | CAPN1 (0.41) | CAPN1SLC7A5CTSBLARS1 | |
| SCHEMBL4232298 | 0.92 | CAPN1 (0.41) | CAPN1SLC7A5CTSBLARS1 | |
| SCHEMBL13039705 | 0.92 | CAPN1 (0.41) | CAPN1SLC7A5CTSBLARS1 | |
| SCHEMBL17347917 | 0.90 | CAPN1 (0.48) | CAPN1SLC7A5CTSBLARS1 | |
| SCHEMBL14899283 | 0.90 | CAPN1 (0.45) | CAPN1SLC7A5CTSBLARS1SCN9A | |
| SCHEMBL2739549 | 0.89 | CAPN1 (0.44) | CAPN1SLC7A5CTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024229370-A1 | COMPOSITIONS AND METHODS FOR TREATING GVHD | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229350-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS FOR DIABETES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229380-A1 | IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS IN AUTOIMMUNE LIVER DISEASES | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| WO-2024229432-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | CARTESIAN THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4429662-A1 | MULTIPLE DOSING WITH VIRAL VECTORS | Cartesian Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4415760-A1 | VIRAL VECTOR DOSING PROTOCOLS | Cartesian Therapeutics, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4319747-A1 | SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE | Selecta Biosciences, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-115011418-B | Liquid composition with stabilized protease activity | 南京百斯杰生物工程有限公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-4274571-A1 | VIRAL VECTOR DOSING PROTOCOLS | Selecta Biosciences, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023196566-A1 | HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND IMMUNOSUPPRESSANTS TO ENHANCE IMMUNE TOLERANCE | SELECTA BIOSCIENCES, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3976802-A1 | METHODS AND COMPOSITIONS FOR ATTENUATED ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSE | Selecta Biosciences, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3962537-A1 | METHODS FOR TREATMENT OF SUBJECTS WITH PREEXISTING IMMUNITY TO VIRAL TRANSFER VECTORS | Selecta Biosciences, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022022599-A1 | METHOD FOR AMPLIFYING IN-VITRO INDUCED CD4 +FOXP3 +CD69 +TREG AND USE THEREOF | 浙江大学 | 2022-02-03 | — | — | WO | disclosed |
| US-11041207-B2 | Method for predicting a subject's response to valproic acid therapy | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2021-06-22 | — | — | US | disclosed |
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | AKRON MOLECULES AG (AT) | 2014-11-27 | — | — | US | disclosed |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | AKRON MOLECULES GMBH (AT) | 2013-09-26 | — | — | US | disclosed |
| EP-2373797-A1 | SCREENING METHOD FOR IDENTIFYING GENES INVOLVED IN PLANT CELL CYCLE | VIB VZW (BE) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066849-A1 | SCREENING METHOD FOR IDENTIFYING GENES INVOLVED IN PLANT CELL CYCLE | VIB VZW (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100068147-A1 | DENGUE DIAGNOSIS AND TREATMENT | Agency for Science , Technology and Research (SG) | 2010-03-18 | — | — | US | disclosed |
| WO-1997032605-A1 | CYTOMEGALOVIRUS NUCLEIC ACIDS ENCODING PROTEINS HAVING NORMAL OR ALTERED CLASS I MHC BINDING AND TREATMENT OF DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349969-A1 | COMPOUNDS AND METHODS FOR TREATING PAIN | TRPV1, ACHE, OPRL1 | CAPN1 1340/4885SLC7A5 4209/4885CTSB 345/4885 |
| US-20130252924-A1 | Compounds and Methods for Treating Pain | TRPV1, ACHE, OPRL1 | CAPN1 1340/4885SLC7A5 4209/4885CTSB 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.